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Abstract: An increasing body of evidence suggests the likelihood of a link between venous 
and arterial thrombosis. The two vascular complications share several risk factors, such as 
age, obesity, diabetes mellitus, blood hypertension, hypertriglyceridemia, and metabolic 
syndrome. Moreover, there are many examples of conditions accounting for both venous and 
arterial thrombosis, such as the antiphospholipid antibody syndrome, hyperhomocysteinemia, 
malignancies, infections, and the use of hormonal treatment. Finally, several recent studies 
have consistently shown that patients with venous thromboembolism are at a higher risk of 
arterial thrombotic complications than matched control individuals. We, therefore, speculate the 
two vascular complications are simultaneously triggered by biological stimuli responsible for 
activating coagulation and inﬂ  ammatory pathways in both the arterial and the venous system. 
Future studies are needed to clarify the nature of this association, to assess its extent, and to 
evaluate its implications for clinical practice.
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Introduction
Venous and arterial thrombotic disorders have long been viewed as separate 
pathophysiological entities, partly as a result of the obvious anatomical differences, as 
well as their distinct clinical presentations. In particular, arterial thrombosis has long 
been held to be largely a phenomenon of platelet activation, whereas venous thrombosis 
is largely a matter of activation of the clotting system. However, there is evidence that 
this dichotomy is likely to be an oversimpliﬁ  cation. Fibrin-rich thrombi form in the left 
atrial appendage of patients with atrial ﬁ  brillation and in the coronary artery system 
of patients with myocardial infarction. Accordingly, anticoagulant drugs are highly 
effective for prevention of arterial embolism related to atrial ﬁ  brillation,1 and for pre-
vention and treatment of coronary artery disease.2 Likewise, platelets play an inevitable 
role in the formation of thrombi in the venous system, and antiplatelet agents have been 
shown to be effective for prevention of venous thromboembolic disorders, although to 
a smaller extent than anticoagulant drugs.3,4 As another example, subjects who sustain 
a retinal vein thrombosis commonly have associated cardiovascular risk factors,5 and 
the causes of mortality on follow-up are usually arterial vascular events.6
Association between venous thromboembolism 
(VTE) and atherosclerosis
A potential association between venous thromboembolism (VTE) and atherosclerosis 
was described in 2003.7 Ultrasonography of the carotid arteries was performed in 299 
unselected patients with deep vein thrombosis (DVT) without symptomatic athero-
sclerosis and in 150 control subjects. In a multivariate analysis taking into account 
risk factors for atherosclerosis, the odds ratio (OR) for carotid plaques in patients with Clinical Epidemiology 2009:1 2
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unprovoked as compared to secondary DVT and controls was 
found to be 2.4, and was highly statistically signiﬁ  cant.
Subsequently, two studies provided further evidence 
supporting the association between VTE and atherosclero-
sis. In a case-control study, Hong and colleagues found a 
higher prevalence of coronary artery calcium, as assessed 
by chest computed tomography (CT) scan, in patients with 
unprovoked VTE than in matched control individuals.8 In a 
series of almost 24,000 consecutive autopsies, Eliasson and 
colleagues found an increased prevalence of VTE in patients 
with arterial thrombosis, except for those with coronary 
artery thrombosis.9
Recently, Ageno and colleagues reviewed the evidence 
favoring the association of the most important risk factors for 
atherosclerosis and VTE.10 After reviewing 21 case-control 
and cohort studies dealing with a total of 63,552 patients 
meeting the inclusion criteria, factors that were found to be 
signiﬁ  cantly associated with an increased risk of VTE were 
obesity, blood hypertension, diabetes mellitus, and hyper-
triglyceridemia. Of interest, weighted mean high-density 
lipoprotein cholesterol levels were signiﬁ  cantly lower in VTE 
patients, whereas no difference between VTE and non-VTE 
patients for total and low-density lipoprotein cholesterol 
levels was found.10
Although information coming from the above reported 
investigations suggests the existence of an association 
between VTE and atherosclerosis, it does not clarify the 
nature of this association. On the one hand, atherosclerosis 
has the potential to promote the development of throm-
botic disorders in the venous system. Atherosclerosis is 
associated with a detectable activation of both platelets and 
blood coagulation as well as an increased ﬁ  brin turnover, 
which can lead to thrombotic complications.11–14 The role 
of this prothrombotic state in favoring venous thrombotic 
events is plausible given the assumption that activated 
platelets and coagulation factors appear in the slow-ﬂ  owing 
venous system. On the other hand, the two clinical conditions 
may share common mechanisms or risk factors. In nature, 
there are many examples of conditions accounting for both 
arterial and venous thromboembolic disorders, such as 
hyperhomocysteinemia,15 antiphospholipid antibodies,16 
malignancies,17 paroxysmal nocturnal hemoglobinuria,18 
infectious states,19 and the use of hormonal therapy.20
Is atherosclerosis predictive of VTE?
In an attempt to assess whether atherosclerotic disease 
predisposes to VTE, the authors of two similar population-
based cohort studies carried out in the US, the Atherosclerosis 
Risk in Communities and the Cardiovascular Health Study, 
evaluated the rate of VTE development in subjects younger 
and older than 65, respectively, who had carotid ultrasound 
and the assessment of other subclinical parameters of 
atherosclerosis, and were then followed-up prospectively 
for several years.21,22
In the former study, 13,081 adults aged 45–64 years 
underwent carotid ultrasonography to assess the intima-
media thickness and the presence of atherosclerotic plaques.21 
After adjustment for age, sex, ethnicity, body mass index, 
and diabetes, no association was found between ultrasound 
parameters of subclinical atherosclerosis and VTE develop-
ment after a mean follow-up of 12.5 years (adjusted hazard 
ratio [HR] of VTE for presence of carotid plaques, 0.97; 95% 
conﬁ  dence interval [CI], 0.72 to 1.29).
In the latter study, 4108 individuals aged at least 65 years 
underwent non-invasive assessment of subclinical atheroscle-
rosis using carotid ultrasound (intima-media thickness and 
presence of plaques), ankle-brachial blood pressure index and 
electrocardiogram, and then were followed-up for a median 
of 11.7 years.22 Surprisingly enough, the adjusted relative 
risk (RR) of overall and idiopathic VTE for presence of any 
type of subclinical atherosclerosis was 0.60 (95% CI, 0.39 
to 0.91) and 0.32 (95% CI, 0.18 to 0.59), respectively. These 
unexpected ﬁ  ndings were mostly explained by an inverse 
association of high-risk carotid plaques or arterial events 
during follow-up.
Based on these ﬁ  ndings, asymptomatic atherosclerosis 
is unlikely to constitute a risk factor of venous thromboem-
bolic disorders. Whether patients developing symptomatic 
complications of atherosclerosis such as myocardial infarc-
tion or stroke are at a higher risk of VTE complications 
is controversial. While in the former of the two above 
reported studies, the occurrence of cardiovascular and cere-
brovascular events was signiﬁ  cantly associated with the 
development of VTE,21 in the latter the opposite was seen.22 
In an attempt to determine the impact of cardiovascular 
risk factors, including family history of myocardial infarc-
tion, on the incidence of VTE, Braekkan and colleagues 
extracted data from 21,330 subjects, aged 25–96 years, who 
had been enrolled in a prospective, population-based study 
(the Tromsø Study).23 In multivariable analysis, family his-
tory of myocardial infarction was signiﬁ  cantly associated 
with both total VTE (HR, 1.27; 95% CI, 1.01–1.60) and 
unprovoked VTE (HR, 1.46; 95% CI, 1.03–2.07. Finally, 
in a recent population-based study conducted in Denmark 
patients with a history of arterial cardiovascular events had a 
clearly increased relative risk of VTE events in the ﬁ  rst three Clinical Epidemiology 2009:1 3
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months following the index event, then the risk decreased 
yet remained statistically signiﬁ  cant.24
Is   VTE predictive of arterial 
cardiovascular events?
Another scenario assumes that the same biological trigger 
is responsible for activating coagulation and inﬂ  ammatory 
pathways in both arterial and venous thromboembolism, in 
such a way determining a simultaneous risk of arterial and 
venous thrombotic complications. If this is true, subjects 
with VTE may be at a higher risk of subsequent arterial 
cardiovascular events than matched control individuals. 
This hypothesis has recently been tested in seven studies 
(summarized in Table 1).
The incidence of arterial cardiovascular events after VTE 
was assessed for the ﬁ  rst time in a long-term prospective 
study on the long-term follow-up in 360 patients with a ﬁ  rst 
episode of pulmonary embolism (PE), of whom 209 with 
idiopathic PE and 151 with PE associated with transient risk 
factors.25 The study outcomes were cardiovascular events 
(recurrent VTE, acute myocardial infarction, stroke, sudden 
otherwise unexplained death), cardiovascular death, and death 
due to any cause. After a median follow-up of 38 months, a 
cardiovascular event occurred in 47 patients with idiopathic 
PE (7.5% patient-year, and in 17 patients with PE associated 
with transient risk factors (3.1% patient-year) (RR, 2.0; 95% 
CI, 1.20 to 3.34). Twenty patients with idiopathic PE (3.2% 
patient-year) and 2 patients with PE associated with transient 
risk factors (0.4% patient-year) presented with an arterial 
cardiovascular events (RR, 7.2; 95% CI, 1.71 to 30.45). 
After adjusting for age, the idiopathic nature of the index PE 
was conﬁ  rmed to be an independent risk factor for arterial 
cardiovascular events at the long-term follow-up.
Later, we reported the results of a prospective follow-up 
study in 1919 consecutive patients with a ﬁ  rst VTE episode.26 
The primary outcome was nonfatal and fatal symptomatic 
atherosclerotic disease (including fatal and nonfatal coronary 
heart disease, fatal and nonfatal ischemic stroke, symptomatic 
peripheral artery disease, fatal heart failure from ischemic 
and/or hypertensive cardiopathy, and sudden otherwise 
inexplicable death) in patients with VTE of unknown origin 
as compared to those with secondary VTE. After a median 
follow-up of 48 and 51 months, respectively, at least one 
symptomatic atherosclerotic complication was detected in 
160 of the 1063 patients (15.1%) with VTE of unknown 
origin, and in 73 of the 856 (8.5%) with secondary VTE. After 
adjusting for age and other risk factors of atherosclerosis, 
the HR for symptomatic atherosclerotic complications in 
patients with VTE of unknown origin compared to those with 
secondary VTE was 1.6 (95% CI, 1.2–2.0). When the analy-
sis was restricted to patients without previous symptomatic 
atherosclerosis, the HR became 1.7 (95% CI, 1.1–2.4).
In the recently published study by Schulman and 
colleagues, reporting on the extended 10-year follow-up of 
the DURAC study in 897 patients with VTE who had been 
randomized to receive six weeks or six months of vitamin K 
antagonists,27 the overall mortality (28.5%) was higher than 
that expected in the general population with a standardized 
incidence ratio (SIR) of 1.43 (95% CI, 1.28 to 1.58), mainly 
because of a higher mortality than expected from cancer 
(SIR, 1.83; 95% CI, 1.44 to 2.23), and from myocardial 
infarction or stroke (SIR, 1.28; 95% CI, 1.00 to 1.56).28
Table 1 Main studies addressing the risk of arterial cardiovascular events in patients with VTE
Ref Study design Study population Number Findings
25 Prospective cohort Idiopathic PE 
Secondary PE
209 
151
Idiopathic PE risk factor of arterial 
cardiovascular events
26 Prospective cohort Idiopathic VTE 
Secondary VTE
1,063 
856
Idiopathic VTE risk factor of arterial 
cardiovascular events
28 Extended follow-up 
of the DURAC study27
VTE patients 
General Swedish population
897 Higher mortality from myocardial 
infarction or stroke in VTE patients
29 Retrospective cohort DVT patients Controls 151 
151
Idiopathic VTE risk factor of arterial 
cardiovascular events
30 Prospective cohort DVT with residual thrombosis 
DVT with recanalized veins
173
143
Residual thrombosis risk factor 
of vascular death
32 Population-based VTE patients Controls 42,124
163,566
VTE risk factor of myocardial infarction 
or stroke
33 Population-based Idiopathic VTE Controls 6,065
12,040
Idiopathic VTE in patients aged 40 
risk factor of myocardial infarction
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism;   VTE, venous thromboembolism.Clinical Epidemiology 2009:1 4
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Bova and colleagues explored the rate of subsequent 
arterial events in patients with unprovoked VTE and control 
subjects.29 In a retrospective cohort study, they compared 
the rate of subsequent arterial events (ie, acute myocardial 
infarction, ischemic stroke and peripheral arterial disease) 
in 151 consecutive patients with objectively conﬁ  rmed 
spontaneous VTE and 151 control subjects randomly 
selected from the database of two family physicians. They 
collected information about cardiovascular risk factors 
(hypertension, hypercholesterolemia, diabetes, obesity, and 
smoke) at the time of VTE episode, or corresponding date 
for the controls, and considered the follow-up from this time. 
During a mean follow-up of 43 months there were 16 arte-
rial events in the VTE patients and six in the control group, 
corresponding to an HR of 2.84; 95% CI, 1.11 to 7.27. The 
difference remained signiﬁ  cant after adjusting for age and 
other cardiovascular risk factors (adjusted HR, 2.86; 95% CI, 
1.07 to 7.62). Overall mortality was also higher in the VTE 
patients (12 vs 4 deaths).
Young and colleagues followed over ﬁ  ve years a cohort 
of 316 patients with acute DVT.30 The patients were divided 
into those with completely clear vessels on follow-up scan 
(45%) and those with residual thrombus identiﬁ  ed (55%). 
As expected, patients with residual thrombus on follow-up 
ultrasound were at higher risk of recurrence, which remained 
signiﬁ  cant after multivariate adjustment for age, gender and 
malignancy (adjusted HR, 2.2; 95% CI, 1.15 to 4.17). During 
follow-up, the cumulative mortality was 12% at two years 
and 27% by ﬁ  ve years. The risk of death was increased in 
patients with residual thrombus at follow-up scan, and this 
risk persisted after multivariate analysis of age, gender 
and malignancy (adjusted RR, 2.8; 95% CI, 1.37 to 5.72). 
Although the majority of deaths were due to malignancy 
(68%), 10 patients (18%) died from vascular causes. There 
was a trend towards increased vascular death in the patients 
with residual thrombus on follow up ultrasound scan, which 
did not reach signiﬁ  cance (HR, 4.1; 95% CI, 0.87 to 19.33).
The increased risk of death in patients with residual thrombus, 
with a trend towards increased vascular death, may suggest 
that failure of thrombus resolution, a well known risk factor 
of recurrent thromboembolism,31 is a marker of more global 
vascular dysfunction.
In a recent population-based cohort study using 
nationwide Danish medical databases, Sorensen and 
colleagues assessed the risk of hospitalization due to 
myocardial infarction, stroke and transient ischemic attack 
among 25,199 patients with DVT, 16,925 patients with 
PE, and 163,566 population controls.32 Patients with both 
DVT and PE were found to have a substantially increased 
risk of myocardial infarction and stroke during the ﬁ  rst 
year after the thrombotic event. For patients with DVT, 
the relative risks varied from 1.60 for myocardial infarc-
tion (95% CI, 1.35–1.91) to 2.19 (95% CI, 1.85–2.60) 
for stroke. For patients with PE, the relative risks were 
2.60 (95% CI, 2.14–3.14) for myocardial infarction and 
2.93 (95% CI, 2.34–3.66) for stroke. The relative risks were 
also elevated, though less markedly, during the subsequent 
20 years of follow-up, with 20% to 40% increases in risk for 
arterial cardiovascular events. Relative risks were similar for 
those with provoked and unprovoked DVT and PE.
Spencer and colleagues performed a longitudinal 
matched cohort study utilizing multiple administrative 
databases.33 Six thousand and sixty ﬁ  ve Ontario residents 
aged 20–64 years diagnosed with unprovoked VTE from 
1 April 1991 to 31 March 1995 were matched to a population 
cohort (n = 12,040) in 1:2 fashion on the basis of age, gender, 
socioeconomic class, cardiovascular risk factors and other 
comorbidities. Patients 20–39 years of age presenting with 
unprovoked VTE had an increased risk of myocardial infarc-
tion (HR, 3.92; 95% CI, 1.65–9.35) as compared to controls; 
the association was applicable to those without atheroscle-
rotic risk factors at baseline. There was no signiﬁ  cant rela-
tionship between unprovoked VTE and AMI among patients 
40–64 years old, with or without atherosclerotic risk factors. 
Irrespective of age, patients with unprovoked VTE had an 
increased risk of all-cause death or our composite endpoint 
of AMI and/or death as compared to patients without VTE.
All together, the results of these studies are in keeping 
with the observation of a higher prevalence of carotid 
atherosclerosis in patients with unprovoked DVT than in 
matched control individuals,7 and suggest that patients with 
VTE have also an increased risk of subsequent symptomatic 
arterial cardiovascular events. This implies that arterial and 
venous thrombosis may share common mechanisms or risk 
factors, and may have a common origin in abnormalities 
of various blood constituents. We speculate that venous 
and arterial thrombosis are two aspects of the same disease 
(ie, thrombosis), and that this disease may electively affect 
genetically predisposed individuals resulting in clinically 
manifestations that are, in turn, depending on a variety of 
elements including the age of patients, their lifestyle, and the 
occurrence of co-morbidities and circumstantial factors: the 
venous thrombotic events being more frequent, for example, 
after triggering risk factors such as surgery or trauma, and 
the arterial thrombotic events being more frequent in subjects 
who have developed atherosclerosis.Clinical Epidemiology 2009:1 5
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Conclusions and implications 
of the association
These ﬁ  ndings have several implications for both research 
and medical practice. Patients with VTE of unknown origin 
could be examined for asymptomatic atherosclerosis, in order 
to modify aggressively the risk proﬁ  le in those with abnormal 
test results. Measures could include appropriate counseling 
about lifestyle changes and control of risk factors for ath-
erosclerosis. Interestingly enough, lifestyle factors are likely 
to have a major impact on the risk of VTE. A diet including 
more plant food and ﬁ  sh and less red and processed meat,34 the 
supplementation of vitamin E,35 regular sports activities,36 and 
alcohol consumption37 have recently been found to be associ-
ated with a lower incidence of venous thrombosis. Consistent 
with these ﬁ  ndings are the results of a prospective cohort study 
conducted in Sweden on 40,000 Swedish women who were 
followed-up for a mean of 11 years: female nonsmokers who 
were physically active and who consumed alcohol in modera-
tion were found to have a lower risk of VTE.38
In addition, a potential role for prophylaxis of both recur-
rent VTE and arterial cardiovascular events with antiplatelet 
therapy or statins may be explored. Interest in statins has 
increased, given recent data that suggest a potential role 
both in controlling the development of atherosclerotic lesions 
and in lowering the risk of venous thromboembolism.39
The currently available evidence for a role of aspirin in 
VTE prevention and treatment is quite limited. Data on the 
long-term management of VTE will be provided by two twin 
studies currently ongoing in Italy (Warfasa) and in Australia 
and New Zealand (Aspire).40 Both studies are aimed at assess-
ing the clinical beneﬁ  t of 100 mg of aspirin given after the 
completion of anticoagulant treatment in patients with a ﬁ  rst 
episode of unprovoked VTE.
In conclusion, the separate nature of arterial and venous 
thrombotic disorders has been challenged. Future studies are 
needed to clarify the nature of this association, to assess its 
extent, and to evaluate its implications for clinical practice.
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